Palforzia

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19
The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19
Endpoints
Nestle
M&A
Aimmune
Palforzia
COVID-19
pandemic
peanut allergy
Flag link:
Nestle pays $2 billion to secure Aimmune’s allergy treatment
Nestle pays $2 billion to secure Aimmune’s allergy treatment
CNBC
Aimmune
Nestle
M&A
peanut allergy
Palforzia
Flag link:
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
Motley Fool
peanut allergy
Viaskin Peanut
DBV Technologies
Aimmune Therapeutics
Palforzia
Flag link:
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing
Xconomy
Aimmune Therapeutics
Palforzia
drug launches
REMS
Jayson Dallas
drug manufacturing
Flag link:
Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor
Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor
Fierce Biotech
Aimmune
Xencor
Nestle
AIMab7195
Palforzia
Flag link:
Aimmune wins approval for peanut immunotherapy, charges 10k+
Aimmune wins approval for peanut immunotherapy, charges 10k+
Endpoints
Aimmune
Palforzia
peanut allergy
FDA
Flag link:
FDA decision nears on Aimmune's contested peanut allergy drug
FDA decision nears on Aimmune's contested peanut allergy drug
BioPharma Dive
FDA
Aimmune
peanut allergy
Palforzia
DBV Technologies
Viaskin Peanut
Flag link:
Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients
Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients
Motley Fool
Aimmune Therapeutics
FDA
Palforzia
peanut allergy
patients
Flag link:
Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug
Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug
NPR
Aimmune Therapeutics
peanut allergy
Palforzia
Flag link:
Aimmune's peanut allergy drug secures FDA panel support, along with criticism
Aimmune's peanut allergy drug secures FDA panel support, along with criticism
Biopharma Dive
Aimmune
FDA
peanut allergy
advisory panel
Palforzia
AR 101
Flag link:
An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening
An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening
Stat
FDA
advisory panels
peanut allergy
Aimmune Therapeutics
Palforzia
Flag link:
No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile
No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile
Endpoints
Aimmune
FDA
peanut allergy
Palforzia
AR101
Flag link: